|
Volumn 21, Issue 129, 2012, Pages 181-
|
Pioglitazone: European approval maintained despite the acknowledged risks
[No Author Info available]
|
Author keywords
[No Author keywords available]
|
Indexed keywords
INSULIN;
METFORMIN;
METFORMIN PLUS PIOGLITAZONE;
PIOGLITAZONE;
BLADDER CANCER;
CANCER RISK;
DRUG APPROVAL;
DRUG CONTROL;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG MARKETING;
EUROPE;
HEART FAILURE;
PRESCRIPTION;
REIMBURSEMENT;
RISK ASSESSMENT;
RISK BENEFIT ANALYSIS;
SHORT SURVEY;
TREATMENT RESPONSE;
DIABETES MELLITUS, TYPE 2;
FRANCE;
HUMANS;
HYPOGLYCEMIC AGENTS;
RISK;
THIAZOLIDINEDIONES;
URINARY BLADDER NEOPLASMS;
|
EID: 84864533318
PISSN: 11677422
EISSN: None
Source Type: Journal
DOI: None Document Type: Short Survey |
Times cited : (2)
|
References (7)
|